Therapeutic Compound for Cancer and Neurodegeneration via Mitochondrial Preservation

BACKGROUND

This invention addresses a major gap in cancer treatment: cancer cells often become resistant to standard therapies, making them less effective. By targeting a unique protein (CIC) that cancer cells rely on for energy, this new approach can make existing treatments work better. It has the potential to improve treatments for cancers like breast, lung, and bladder cancer while reducing side effects.

Benefit

• This method provides a targeted approach to treating cancers (breast, lung, and bladder) and neurodegenerative diseases (e.g., Parkinson's).
• The invention increases treatment options for these conditions, offering potential benefits such as slowed disease progression, improved symptom management, and effective synergy when combined with other therapeutic agents.

Market Application

• Enhancing treatment for drug-resistant cancers like lung, breast, and bladder cancer by specifically targeting the energy needs of cancer cells
• May protect against neurodegeneration in conditions like Parkinson’s disease, providing a novel approach to neuroprotective therapies.
• Potential to slow aging processes and improve outcomes in diabetes, presenting new preventive treatments for age-related conditions.

Publications

• Catalina-Rodriguez O, Kolukula VK, Tomita Y, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012;3(10):1220-1235. doi:https://doi.org/10.18632/oncotarget.714
• Fernandez HR, Gadre SM, Tan M, et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death & Differentiation. 2018;25(7):1239-1258. doi:https://doi.org/10.1038/s41418-018-0101-z
• Tan M, Rami Mosaoa, Graham GT, et al. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death and Differentiation. 2020;27(7):2143-2157. doi:https://doi.org/10.1038/s41418-020-0491-6
• Rami Mosaoa, Kasprzyk-Pawelec A, Fernandez HR, Avantaggiati ML. The Mitochondrial Citrate Carrier SLC25A1/CIC and the Fundamental Role of Citrate in Cancer, Inflammation and Beyond. Biomolecules. 2021;11(2):141-141. doi:https://doi.org/10.3390/biom11020141

Intellectual property status

Granted Patent

Patent number : 9,545,388 and CONT 14/437,727

Where : USA